Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

Completed · Phase 1

Conditions studied: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms

In brief

RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 in treating patients with myelodysplastic syndrome.

Key facts

Study ID

NCT00002746

Run by

University of Washington

People needed

24

Starts

1996-01-01

Expected to finish

2004-04-01

Last updated by the study team

2019-02-27

Who can join

Age: 15 and older, up to 120. Sex: any. Healthy volunteers: not accepted.

Where it is running

• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.